Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder

International Journal of Biological Markers

Volumn 18, Issue 4, 2003, Pages 284-289

  El Kenawy, A El Meghawry ^a   El Kott, A F ^a   Khalil, A M ^b  

^a MENOUFIA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Bladder cancer; Immunohistochemistry; MDM2; Overexpression; p53; Squamous cell carcinoma

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTECTOMY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE FUNCTION; GENE INACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR MECHANICS; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHISTOSOMIASIS; SQUAMOUS CELL CARCINOMA; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 1242297013     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/jbm.2008.2927     Document Type: Article

References (25)

1. Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettlinc C, Menck HR. The national cancer data report on bladder carcinoma. Cancer 1996; 77: 1505-13.
2. Badawi AF. Molecualar and genetic events in schistosomiasis associated human bladder cancer. Role of oncogenes and tumor suppressor genes. Cancer Lett 1996, 105: 123-38.
3. Klug SW, Cummings RM. Concepts of genetics. Upper Saddle River, New ]ersey: Prentice Hall, 1994.
4. Glick HS, Howell PL, White RW. Relationship of p53 and bcl 2 to prognosis in muscle invasive transitional cell carcinoma of the bladder. J Urol 1996; 155: 1754-7.
5. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 233: 49-53.
6. Knowles AM. Molecular genetics of bladder cancer. Br J Urol 1995 (75 suppl 1): 57-66.
7. La Rue H, Allard P, Simoneau M, et al. p53 point mutations in intial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis 2000; 21: 101-6.
8. Darnton SJ. Demystified... p53. Mol Pathol 1998; 51: 248-53.
9. Lu ML, Wikman F, Orntoft TF, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by convertional and array-based methods. Clin Cancer Res 2002; 8: 171-9.
10. Piette J, Neel H, Marechal V. Mdm2: keeping p53 under control. Oncogen 1997; 28, 15: 1001-10.
11. Alarcon-Vargas D, Ronai Z. p53-Mdm2 - the affair that never ends. Carcinogenesis 2002; 23: 541-7.
12. Haines DS. The mdm2 proto-oncogene. Leuk Lymphoma 1997; 26: 227-38.
13. Momand J, Wu HH, Dasgupta G. MDM2 - master regulator of the p53 tumor suppressor protein. Gene 2000; 25: 15-29.
14. Freedman DA, Wu L, Levine AJ. Function of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55: 96-107.
15. Schmitz-Drager BJ, Kushima M, Goebell P, et al. p53 and MDM2 in the development and progression of bladder cancer. Eur Urol 1997; 32: 487-93.
16. Lianes P, Orlow I, Zhang ZF, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994; 86: 1325-30.
17. Osman I, Scher H, Zhang ZF, et al. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer. Clin Cancer Res 1997; 3: 531-6.
18. Parmer MK, Freeman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer. J Urol 1989; 142: 284-8.
19. Reznikoff CA, Belair CD, Yeager TR, et al. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 1996; 23: 571-84.
20. Esrig D, Spruck CH, Nichols PW, et al. p53 nuclear accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389-97.
21. Momand J, Zambetti GP. MDM2: "big brother" of p53. J Cell Biochem 1997; 64: 343-52.
22. Mahran MR, El-Baz M. Verrucous carcinoma of the bilharzial bladder. Impact of invasiveness on survival. Scand J Urol Nephrol 1993; 27: 189-92.
23. Haitel A, Posch B, El-Baz M, et al. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. J Urol 2001; 165: 1481-7.
24. Shaaban AA, Javadpour N, Tribukait B, Ghoneim MA. Prognostic significance of flow DNA analysis and cell surface isoantigens in carcinoma of bilharzial bladder. Urology 1992; 39: 207-10.
25. Ghoneim MA, El-Mekresh MM, Mokhtar AA, Gomha MA, EL-Baz MA, EL-Attar IA. A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int 2000; 85: 811-6.